Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.

Inclusion Criteria:

• KHE patients who have received sirolimus treatment and met the criteria for drug discontinuation.
• With evaluable clinical or imaging parameters to monitor disease activity or recurrence.
• Patients or their guardians are able to understand the study and provide written informed consent.
• Hematologic and hepatic/renal function meet the safety criteria for drug administration.

Exclusion Criteria:

• Patients who are unable to comply with the follow-up or treatment schedule, potentially affecting the integrity of study data.